1. <rp id="po1xj"></rp>

      <tbody id="po1xj"></tbody>

    2. <dd id="po1xj"><pre id="po1xj"></pre></dd>
    3. <tbody id="po1xj"></tbody>
      1. <dd id="po1xj"><noscript id="po1xj"></noscript></dd>
        <th id="po1xj"></th>
        CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer
        Shi Chen # 1 2, Can Yang # 3, Zu-Wei Wang # 3, Jian-Fei Hu # 3, Jing-Jing Pan 3, Cheng-Yu Liao 3, Jia-Qiang Zhang 4, Jiang-Zhi Chen 5, Yi Huang 3 6, Long Huang 3 7, Qian Zhan 4, Yi-Feng Tian 3 7, Bai-Yong Shen 8, Yao-Dong Wang

        The CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2, which promotes growth and metastasis and regulates m6A methylation of PDAC cells. This study suggests the potential prognostic value and therapeutic targeting of this pathway in PDAC patients.

        J Hematol Oncol. 2021 Apr 13;14(1):60. 

        NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis
        Barbora Pekova 1,*OrcID,Vlasta Sykorova 1OrcID,Karolina Mastnikova 1,Eliska Vaclavikova 1,Jitka Moravcova 1,Petr Vlcek 2,Petr Lastuvka 3,Milos Taudy 3,Rami Katra 4OrcID,Petr Bavor 5,Daniela Kodetova 6,Martin Chovanec 7OrcID,Jana Drozenova 8,Jaromir Astl 9

        NTRK fusion genes are valuable diagnostic and prognostic markers.

        Cancers 2021, 13(8), 1932

        "Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer"
        "Yuanyuan Wang1*, Zhi Zhao2*, Jing Zhuang3, Xinxin Wu4, Zhizhong Wang4, Bing Zhang1, Ge Gao1, Yinping Zhang1, Caili Guo5, Qingxin Xia"

        High LC3 protein expression shows a certain prognostic value in CRC patients. LC3, the MSI status, and KRAS mutations must be considered when selecting an adjuvant therapy for CRC. The detection of these indexes is of great significance to identify high-risk patients who would benefit from autophagy-related anticancer drugs or help to explore more effective treatment options for patients who are resistant to conventional chemotherapy or relapse.

        Journal of Cancer. 2021; 12(12): 3515-3528.

        Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
        Xiaohong Wang 1, Yonggang Liu 1, Zhiying Meng 1, Yun Wu 2, Shubin Wang 2, Gaowa Jin 3, Yingchun Qin 3, Fengyun Wang 4, Jing Wang 4, Haifei Zhou 5, Xiaoxing Su 5, Xiuhua Fu 6, Xiaolan Wang 7, Xiaoyu Shi 8, Zhenping Wen 9, Xiaoqiong Jia 9, Qiong Qin 10, Yon

        Liquid biopsy screening based on highly sensitive NGS is reliable for detecting drug resistance and actionable somatic mutations. The plasma abundance of the EGFR driver mutation affected clinical response to EGFR-TKIs in advanced NSCLC patients; prolongation of PFS was also observed in patients with an ultra-low abundance of EGFR sensitizing mutations.

        Ann Transl Med. 2021 Apr;9(8):635. 

        MLH1/PMS2 Expression Could Tell Classical NTRK Fusion in Fluorescence In Situ Hybridization Positive Colorectal Carcinomas
        Yao Fu, 1 , ? Zheng Li, 2 , ? Fuping Gao, 3 , ? Jun Yang, 1 Hongyan Wu, 1 Biao Zhang, 1 Xiaohong Pu, 1 , * and Xiangshan Fan

         if patients are going to undergo TRK-based targeted therapy, only RNA-based NGS for detection of the specific fusion could tell the precise rearrangement information.

        Front Oncol. 2021 Apr 29;11:669197. 

        Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
        Yue-Yun Chen 1, Pei-Pei Wang 1, Yang- Fu 1, Qing- Li 1, Jiang-Fang Tian 1, Ting- Liu 1, Zhen Lin 1, Zhen-Yu Ding

        BoM was identified as an independent inferior prognostic factor for EGFR-TKI treatment, and may have complex biological implications.

        J Bone Oncol. 2021 May 4;29:100369.